Akero Therapeutics, Inc. (AKRO) Insider Trading Activity
NASDAQ$40.01
Market Cap
$3.19B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
31 of 878
Rank in Industry
24 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
AKRO Insider Trading Activity
AKRO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $18,387,921 | 4 | 5 |
Sells | $42,661,477 | 77 | 95 |
Related Transactions
| Graham G. Walmsley | director | 4 | $18.39M | 0 | $0 | $18.39M |
| Lamy Patrick | Senior VP, Commercial Strategy | 0 | $0 | 6 | $743,683 | $-743,683 |
| Rolph Timothy | Chief Scientific Officer | 0 | $0 | 11 | $4.74M | $-4.74M |
| White William Richard | Chief Financial Officer | 0 | $0 | 10 | $6.66M | $-6.66M |
| Young Jonathan | Chief Operating Officer | 0 | $0 | 15 | $7.13M | $-7.13M |
| Yale Catriona | Chief Development Officer | 0 | $0 | 22 | $10.19M | $-10.19M |
| Cheng Andrew | President and CEO | 0 | $0 | 13 | $13.2M | $-13.2M |
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Activity of Akero Therapeutics, Inc.
Over the last 12 months, insiders at Akero Therapeutics, Inc. have bought $18.39M and sold $42.66M worth of Akero Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akero Therapeutics, Inc. have bought $27.77M and sold $37.27M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Graham G. Walmsley (director) — $18.39M.
The last purchase of 50,000 shares for transaction amount of $2.18M was made by Graham G. Walmsley (director) on 2025‑03‑27.
List of Insider Buy and Sell Transactions, Akero Therapeutics, Inc.
| 2025-05-07 | Sale | Lamy Patrick | Senior VP, Commercial Strategy | 8,000 0.01% | $42.49 | $339,950 | -2.36% | |
| 2025-05-06 | Sale | Rolph Timothy | Chief Scientific Officer | 12,500 0.0162% | $43.43 | $542,864 | -4.69% | |
| 2025-04-24 | Sale | Rolph Timothy | Chief Scientific Officer | 6,250 0.0081% | $41.03 | $256,438 | +4.10% | |
| 2025-04-15 | Sale | Yale Catriona | Chief Development Officer | 9,073 0.012% | $37.91 | $343,962 | +9.38% | |
| 2025-04-10 | Sale | Cheng Andrew | President and CEO | 30,000 0.0369% | $35.23 | $1.06M | +18.74% | |
| 2025-04-07 | Sale | Rolph Timothy | Chief Scientific Officer | 6,250 0.0078% | $35.88 | $224,262 | +14.16% | |
| 2025-03-27 | Graham G. Walmsley | director | 50,000 0.0628% | $43.55 | $2.18M | -6.80% | ||
| 2025-03-26 | Graham G. Walmsley | director | 58,691 0.0732% | $43.01 | $2.52M | -5.87% | ||
| 2025-03-25 | Graham G. Walmsley | director | 91,309 0.1134% | $44.75 | $4.09M | -9.58% | ||
| 2025-03-17 | Sale | Yale Catriona | Chief Development Officer | 10,000 0.0125% | $44.76 | $447,605 | -7.24% | |
| 2025-03-12 | Sale | Cheng Andrew | President and CEO | 1,738 0.0021% | $44.88 | $78,001 | -8.97% | |
| 2025-03-12 | Sale | Young Jonathan | Chief Operating Officer | 607 0.0007% | $44.88 | $27,242 | -8.97% | |
| 2025-03-12 | Sale | Rolph Timothy | Chief Scientific Officer | 516 0.0006% | $44.88 | $23,158 | -8.97% | |
| 2025-03-12 | Sale | Yale Catriona | Chief Development Officer | 614 0.0008% | $44.88 | $27,556 | -8.97% | |
| 2025-03-12 | Sale | White William Richard | Chief Financial Officer | 676 0.0008% | $44.88 | $30,339 | -8.97% | |
| 2025-03-10 | Sale | Cheng Andrew | President and CEO | 30,000 0.0378% | $41.77 | $1.25M | +0.65% | |
| 2025-03-05 | Sale | Rolph Timothy | Chief Scientific Officer | 12,500 0.0154% | $44.53 | $556,590 | -6.86% | |
| 2025-03-04 | Sale | Young Jonathan | Chief Operating Officer | 50,000 0.0666% | $44.86 | $2.24M | -5.41% | |
| 2025-03-03 | Sale | Lamy Patrick | Senior VP, Commercial Strategy | 1,000 0.0014% | $48.09 | $48,090 | -7.25% | |
| 2025-02-18 | Sale | Yale Catriona | Chief Development Officer | 10,000 0.0131% | $49.87 | $498,660 | -12.44% |
Total: 259
*Gray background shows transactions not older than one year
Insider Historical Profitability
16.65%
| Graham G. Walmsley | director | 1200000 1.506% | $48.01M | 13 | 0 | +42.32% |
| Cheng Andrew | President and CEO | 624324 0.7835% | $24.98M | 0 | 44 | |
| Young Jonathan | Chief Operating Officer | 200540 0.2517% | $8.02M | 0 | 37 | |
| Rolph Timothy | Chief Scientific Officer | 169721 0.213% | $6.79M | 0 | 25 | |
| Yale Catriona | Chief Development Officer | 95034 0.1193% | $3.8M | 0 | 41 | |
| White William Richard | Chief Financial Officer | 61959 0.0778% | $2.48M | 0 | 27 | |
| Lamy Patrick | Senior VP, Commercial Strategy | 33492 0.042% | $1.34M | 0 | 6 | |
| Apple Tree Partners IV, L.P. | 10 percent owner | 5830203 7.3171% | $233.27M | 2 | 0 | <0.0001% |
| Skorpios Trust | director | 3271829 4.1063% | $130.91M | 0 | 1 | |
| Versant Venture Capital VI, L.P. | 10 percent owner | 3092698 3.8814% | $123.74M | 1 | 22 | +13.18% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 3033552 3.8072% | $121.37M | 1 | 25 | +13.18% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 505099 0.6339% | $20.21M | 1 | 0 | +13.18% |
| Royston Aaron | director | 250000 0.3138% | $10M | 1 | 0 | +13.18% |
| Harrison Seth Loring | director | 136301 0.1711% | $5.45M | 2 | 5 | <0.0001% |
| Henderson Jane | director | 0 0% | $0 | 0 | 1 | |
| Bitterman Kevin | director | 0 0% | $0 | 1 | 2 | +13.18% |
| Heyman Tomas J. | director | 0 0% | $0 | 0 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$11,588,217 | 69 | 42.07% | $2.88B | |
$42,463,802 | 57 | 17.85% | $3.56B | |
$140,165,669 | 33 | 85.24% | $2.38B | |
$1,275,975,557 | 32 | 19.44% | $2.88B | |
$11,859,102 | 17 | 18.62% | $3.66B | |
$103,944,213 | 17 | 5.95% | $3.61B | |
$128,181,928 | 16 | 18.84% | $2.83B | |
$74,605,681 | 14 | 47.06% | $3.21B | |
Akero Therapeutics, Inc. (AKRO) | $177,517,505 | 13 | 16.65% | $3.19B |
$57,686,748 | 13 | 21.11% | $3.68B | |
$70,151,579 | 12 | 22.57% | $2.98B | |
$91,269,919 | 12 | 12.86% | $2.9B | |
$35,908,794 | 10 | 126.31% | $2.74B | |
$117,959,652 | 9 | -12.47% | $2.45B | |
$1,711,150 | 9 | 31.59% | $3.11B | |
$4,623,072 | 7 | 11.07% | $3.35B | |
$182,500,000 | 6 | 29.00% | $3.21B | |
$14,400,000 | 5 | 41.34% | $3.48B | |
$36,900,000 | 3 | -9.12% | $3.6B |
AKRO Institutional Investors: Active Positions
| Increased Positions | 126 | +73.26% | 10M | +14.06% |
| Decreased Positions | 73 | -42.44% | 7M | -9.09% |
| New Positions | 52 | New | 4M | New |
| Sold Out Positions | 23 | Sold Out | 368,617 | Sold Out |
| Total Postitions | 225 | +30.81% | 77M | +4.98% |
AKRO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Wellington Management Group Llp | $331,004.00 | 9.22% | 7.38M | -519,671 | -6.58% | 2024-12-31 |
| Rtw Investments, Lp | $307,800.00 | 8.57% | 6.86M | +940,388 | +15.89% | 2024-12-31 |
| Blackrock, Inc. | $280,663.00 | 7.82% | 6.26M | +330,841 | +5.58% | 2025-03-31 |
| Janus Henderson Group Plc | $270,756.00 | 7.54% | 6.03M | -1M | -14.74% | 2024-12-31 |
| General Atlantic, L.P. | $234,849.00 | 6.54% | 5.23M | 0 | 0% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $193,927.00 | 5.4% | 4.32M | +513,613 | +13.49% | 2024-12-31 |
| Vanguard Group Inc | $166,217.00 | 4.63% | 3.7M | +27,830 | +0.76% | 2024-12-31 |
| State Street Corp | $104,814.00 | 2.92% | 2.34M | -167,002 | -6.67% | 2024-12-31 |
| Alliancebernstein L.P. | $82,529.00 | 2.3% | 1.84M | -177,807 | -8.81% | 2024-12-31 |
| Alkeon Capital Management Llc | $79,028.00 | 2.2% | 1.76M | -2M | -47.03% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.